Research
Hormonal
Tirzepatide improves insulin sensitivity by 65.7%, a significantly greater improvement than the 37.5% observed with semaglutide.
Tirzepatide works differently than semaglutide by targeting both GLP-1 and GIP receptors, which leads to a much larger improvement in how your body uses insulin (65.7% vs 37.5%). This enhanced insulin sensitivity contributes to better blood sugar control and greater weight loss.
GoodSupportsHIGH confidence
In the SURPASS-2 study, tirzepatide improved insulin sensitivity by 65.7%, significantly greater than the 37.5% improvement observed with semaglutide.
Why this rating
Based on a specific phase 1 trial (SURPASS-2 mechanistic analysis) cited.
Source
Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
Laura Opalska et al. · Quality in Sport · 2024
DOI 10.12775/qs.2024.35.56425
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide (a dual GIP/GLP-1 receptor agonist) produces significantly greater weight loss and glycemic control than semaglutide (a GLP-1 receptor agonist) in patients with type 2 diabetes and obesity.Strong
- Semaglutide reduces major adverse cardiovascular events (MACE) by 26% in patients with type 2 diabetes at high cardiovascular risk.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →